# A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

> **NCT04645797** · PHASE1 · TERMINATED · sponsor: **Apros Therapeutics, Inc** · enrollment: 11 (actual)

## Conditions studied

- Advanced Colorectal Carcinoma

## Interventions

- **DRUG:** APR003

## Key facts

- **NCT ID:** NCT04645797
- **Lead sponsor:** Apros Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-19
- **Primary completion:** 2022-05-07
- **Final completion:** 2022-05-07
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study terminated prematurely due to internal corporate decision
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04645797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04645797, "A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04645797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*